These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 14563344)

  • 1. The 2373insG mutation in the MYBPC3 gene is a founder mutation, which accounts for nearly one-fourth of the HCM cases in the Netherlands.
    Alders M; Jongbloed R; Deelen W; van den Wijngaard A; Doevendans P; Ten Cate F; Regitz-Zagrosek V; Vosberg HP; van Langen I; Wilde A; Dooijes D; Mannens M
    Eur Heart J; 2003 Oct; 24(20):1848-53. PubMed ID: 14563344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutations in the cardiac myosin-binding protein C gene are the predominant cause of familial hypertrophic cardiomyopathy in eastern Finland.
    Jääskeläinen P; Kuusisto J; Miettinen R; Kärkkäinen P; Kärkkäinen S; Heikkinen S; Peltola P; Pihlajamäki J; Vauhkonen I; Laakso M
    J Mol Med (Berl); 2002 Jul; 80(7):412-22. PubMed ID: 12110947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel deletions in MYH7 and MYBPC3 identified in Indian families with familial hypertrophic cardiomyopathy.
    Waldmüller S; Sakthivel S; Saadi AV; Selignow C; Rakesh PG; Golubenko M; Joseph PK; Padmakumar R; Richard P; Schwartz K; Tharakan JM; Rajamanickam C; Vosberg HP
    J Mol Cell Cardiol; 2003 Jun; 35(6):623-36. PubMed ID: 12788380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of heterozygous and homozygous mouse models with the most common hypertrophic cardiomyopathy mutation MYBPC3
    Hilderink S; Schuldt M; Goebel M; Jansen VJ; Manders E; Moorman S; Dorsch LM; van Steenbeek FG; van der Velden J; Kuster DWD
    J Mol Cell Cardiol; 2023 Dec; 185():65-76. PubMed ID: 37844837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Compound heterozygosity deteriorates phenotypes of hypertrophic cardiomyopathy with founder MYBPC3 mutation: evidence from patients and zebrafish models.
    Hodatsu A; Konno T; Hayashi K; Funada A; Fujita T; Nagata Y; Fujino N; Kawashiri MA; Yamagishi M
    Am J Physiol Heart Circ Physiol; 2014 Dec; 307(11):H1594-604. PubMed ID: 25281569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of a large duplication mutation in the myosin-binding protein C3 gene in a case of hypertrophic cardiomyopathy.
    Meyer T; Pankuweit S; Richter A; Maisch B; Ruppert V
    Gene; 2013 Sep; 527(1):416-20. PubMed ID: 23816408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diastolic abnormalities as the first feature of hypertrophic cardiomyopathy in Dutch myosin-binding protein C founder mutations.
    Michels M; Soliman OI; Kofflard MJ; Hoedemaekers YM; Dooijes D; Majoor-Krakauer D; ten Cate FJ
    JACC Cardiovasc Imaging; 2009 Jan; 2(1):58-64. PubMed ID: 19356534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Novel Founder Mutation in MYBPC3: Phenotypic Comparison With the Most Prevalent MYBPC3 Mutation in Spain.
    Sabater-Molina M; Saura D; García-Molina Sáez E; González-Carrillo J; Polo L; Pérez-Sánchez I; Olmo MDC; Oliva-Sandoval MJ; Barriales-Villa R; Carbonell P; Pascual-Figal D; Gimeno JR
    Rev Esp Cardiol (Engl Ed); 2017 Feb; 70(2):105-114. PubMed ID: 28029522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A founder MYBPC3 mutation results in HCM with a high risk of sudden death after the fourth decade of life.
    Calore C; De Bortoli M; Romualdi C; Lorenzon A; Angelini A; Basso C; Thiene G; Iliceto S; Rampazzo A; Melacini P
    J Med Genet; 2015 May; 52(5):338-47. PubMed ID: 25740977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spectrum of clinical phenotypes and gene variants in cardiac myosin-binding protein C mutation carriers with hypertrophic cardiomyopathy.
    Erdmann J; Raible J; Maki-Abadi J; Hummel M; Hammann J; Wollnik B; Frantz E; Fleck E; Hetzer R; Regitz-Zagrosek V
    J Am Coll Cardiol; 2001 Aug; 38(2):322-30. PubMed ID: 11499719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse events in families with hypertrophic or dilated cardiomyopathy and mutations in the MYBPC3 gene.
    Ehlermann P; Weichenhan D; Zehelein J; Steen H; Pribe R; Zeller R; Lehrke S; Zugck C; Ivandic BT; Katus HA
    BMC Med Genet; 2008 Oct; 9():95. PubMed ID: 18957093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A human MYBPC3 mutation appearing about 10 centuries ago results in a hypertrophic cardiomyopathy with delayed onset, moderate evolution but with a risk of sudden death.
    Teirlinck CH; Senni F; Malti RE; Majoor-Krakauer D; Fellmann F; Millat G; André-Fouët X; Pernot F; Stumpf M; Boutarin J; Bouvagnet P
    BMC Med Genet; 2012 Nov; 13():105. PubMed ID: 23140321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Founder mutations in hypertrophic cardiomyopathy patients in the Netherlands.
    Christiaans I; Nannenberg EA; Dooijes D; Jongbloed RJ; Michels M; Postema PG; Majoor-Krakauer D; van den Wijngaard A; Mannens MM; van Tintelen JP; van Langen IM; Wilde AA
    Neth Heart J; 2010 May; 18(5):248-54. PubMed ID: 20505798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A molecular screening strategy based on beta-myosin heavy chain, cardiac myosin binding protein C and troponin T genes in Italian patients with hypertrophic cardiomyopathy.
    Girolami F; Olivotto I; Passerini I; Zachara E; Nistri S; Re F; Fantini S; Baldini K; Torricelli F; Cecchi F
    J Cardiovasc Med (Hagerstown); 2006 Aug; 7(8):601-7. PubMed ID: 16858239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nationwide study on hypertrophic cardiomyopathy in Iceland: evidence of a MYBPC3 founder mutation.
    Adalsteinsdottir B; Teekakirikul P; Maron BJ; Burke MA; Gudbjartsson DF; Holm H; Stefansson K; DePalma SR; Mazaika E; McDonough B; Danielsen R; Seidman JG; Seidman CE; Gunnarsson GT
    Circulation; 2014 Sep; 130(14):1158-67. PubMed ID: 25078086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insights into genotype-phenotype correlation in hypertrophic cardiomyopathy. Findings from 18 Spanish families with a single mutation in MYBPC3.
    Oliva-Sandoval MJ; Ruiz-Espejo F; Monserrat L; Hermida-Prieto M; Sabater M; García-Molina E; Ortiz M; Rodríguez-García MI; Núñez L; Gimeno JR; Castro-Beiras A; Valdés M
    Heart; 2010 Dec; 96(24):1980-4. PubMed ID: 21088121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical features, spectrum of causal genetic mutations and outcome of hypertrophic cardiomyopathy in South Africans.
    Ntusi NA; Shaboodien G; Badri M; Gumedze F; Mayosi BM
    Cardiovasc J Afr; 2016; 27(3):152-158. PubMed ID: 27841901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Familiar hypertrophic cardiomyopathy caused by a IVS15-1G > A mutation in cardiac myosin-binding protein C gene].
    Zou YB; Wang JZ; Wu GR; Song L; Wang SX; Yu H; Zhang Q; Wang H; Hui RT
    Zhonghua Xin Xue Guan Bing Za Zhi; 2006 Aug; 34(8):699-702. PubMed ID: 17081393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insights Into Hypertrophic Cardiomyopathy Evaluation Through Follow-up of a Founder Pathogenic Variant.
    Lorca R; Gómez J; Martín M; Cabanillas R; Calvo J; León V; Pascual I; Morís C; Coto E; R Reguero JJ
    Rev Esp Cardiol (Engl Ed); 2019 Feb; 72(2):138-144. PubMed ID: 29631964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two founder mutations in the alpha-tropomyosin and the cardiac myosin-binding protein C genes are common causes of hypertrophic cardiomyopathy in the Finnish population.
    Jääskeläinen P; Heliö T; Aalto-Setälä K; Kaartinen M; Ilveskoski E; Hämäläinen L; Melin J; Nieminen MS; Laakso M; Kuusisto J; ; Kervinen H; Mustonen J; Juvonen J; Niemi M; Uusimaa P; Huttunen M; Kotila M; Pietilä M
    Ann Med; 2013 Feb; 45(1):85-90. PubMed ID: 22462493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.